• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Kent Lake Nominates Three Highly Qualified, Independent Candidates for Quanterix Board

    3/3/25 8:00:00 AM ET
    $AKYA
    $CMBM
    $CSCO
    $DOMO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Radio And Television Broadcasting And Communications Equipment
    Technology
    Get the next $AKYA alert in real time by email

    Believes Incumbent Board's Approval and Ongoing Pursuit of Reckless and Dilutive Proposed Merger with Akoya Biosciences Demonstrates Urgent Need for Refreshment

    Nominees Would Bring Deep Healthcare and Financial Experience Necessary to Properly Oversee a Standalone Quanterix, Prevent Further Capital Misallocation and Improve Shareholder Value

    Kent Lake Urges Shareholders to Vote Against Merger with Akoya to Protect the Future Value of Their Investment

    Kent Lake PR LLC ("Kent Lake"), a holder of 6.9% of the outstanding common stock of Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), announced today it has nominated three highly qualified, independent candidates for election to the Company's Board of Directors (the "Board") at the 2025 Annual Meeting of Shareholders (the "Annual Meeting").

    Kent Lake issued the following statement:

    "We have never before taken a public activist stance at any of the companies in which we are invested, let alone nominated director candidates. However, as a top five shareholder in Quanterix, we are appalled by the Company's deeply flawed proposed merger (the "Merger") with Akoya Biosciences ("Akoya") (NASDAQ:AKYA) and cannot stand idly by. We previously detailed the issues with the Merger in our February 13th open letter to shareholders and will not repeat them here. Suffice it to say that the Merger would massively dilute existing shareholders, introduce unnecessary risks and divert focus from the Company's core growth opportunity – and shareholders should not approve it.

    At this point, it is clear that the incumbent Board – which approved and continues to pursue the Merger – has failed in its core responsibility to act in the best interests of shareholders and cannot be trusted to oversee the Company going forward. That is why we have nominated an outstanding slate of three independent candidates to bring accountability, financial discipline and industry expertise to the boardroom.

    There is a better path forward for shareholders, and we believe that they should have the chance to elect directors who can help the Company refocus on its promising organic growth opportunities in the research market while focusing on the transformational Alzheimer's testing opportunity. In our view, substantial value can be unlocked by pursuing such a path.

    We look forward to communicating further with our fellow shareholders in the weeks to come."

    Kent Lake's nominees are:

    Alexander G. Dickinson, PhD

    Dr. Dickinson is a domain expert in life science tools and diagnostics industries and provides valuable perspective as a key industry leader.

    • Former SVP of Strategic Initiatives at Illumina Inc. (NASDAQ:ILMN), an industry pioneer in the life science tools market (spent seven years as Senior VP as revenue grew from $900 million to $2.4 billion)
    • Founder/CEO at Helixis Inc. (acquired by Illumina for $105m)
    • Founder/CEO at Luxtera Inc. (acquired by Cisco (NASDAQ: CSCO) for $660 million)
    • Substantial public and private company board experience at companies providing relevant insight into Quanterix market niches, such as PRA Health Sciences (NASDAQ:PRAH), a leading Clinical Research Organization, that underwent a doubling of market capitalization to $12B prior to its acquisition by ICON (NASDAQ:ICLR)

    Bruce Felt, MBA

    Mr. Felt brings extensive financial leadership and public company board experience, including as CFO for multiple technology and software companies. In addition to meeting the qualifications for a public company Audit Committee Chair, Mr. Felt's deep expertise in corporate finance, M&A and scaling enterprise software businesses makes him invaluable to improving Quanterix's capital allocation, cost structure optimization and accounting systems – including where material weaknesses and restatements have occurred, such as at Quanterix.

    • Served as CFO for multiple technology and software companies, including Domo (NASDAQ:DOMO), SuccessFactors (NASDAQ:SFSF) (acquired by SAP for $3.4B) and FullTime Software (NASDAQ:FTSW) (acquired by Legato Systems), where he led financial strategy, capital allocation and IPO readiness
    • Brings public boardroom experience from Cambium Networks (NASDAQ:CMBM) and past directorships at Evolent Health (NYSE:EVH) and Yodlee (NASDAQ:YDLE), with strong governance and audit committee qualifications
    • Clear capital allocation expertise – led successful acquisitions and financial restructurings, optimizing capital structures and enhancing shareholder value across various enterprises

    Hakan Sakul, PhD

    Dr. Sakul brings extensive expertise in precision medicine, clinical diagnostics and biopharmaceutical R&D, with over two decades of leadership at Pfizer, where he advanced personalized healthcare through innovative diagnostic strategies. His deep experience in clinical diagnostics, regulatory strategy and corporate governance, combined with his board roles in biotech and diagnostics companies, positions him to provide invaluable strategic guidance on diagnostic development, regulatory navigation and healthcare innovation for the Quanterix board.

    • Led Pfizer's (NYSE:PFE) diagnostics division, bringing expertise in scaling and commercializing advanced biomarker technologies that aligns with Quanterix's focus on high-impact diagnostics
    • Currently serves as President & Founder of Precision Dx Strategies and on boards of biotech companies including Progentec Diagnostics, providing strategic insight on positioning diagnostic technologies for clinical adoption – which is critical as Quanterix expands its clinical applications
    • Guided development of companion diagnostics across multiple therapeutic areas including neurology and oncology, directly relevant to Quanterix's focus on neurological biomarkers and expansion into oncology applications
    • Brings deep expertise in translational science, clinical pharmacology and regulatory strategy, which is important for guiding Quanterix through regulatory approvals and accelerating market adoption of its technologies

    About Kent Lake Partners LP

    Kent Lake Partners LP is an investment fund founded by Ben Natter in 2019 with a focus on small and mid-capitalization public equities, particularly in the healthcare space. Mr. Natter has over a decade of successful public healthcare equity investing experience.

    Certain Information Concerning the Participants

    Kent Lake Partners LP ("Kent Lake Partners"), together with the other Participants (as defined below), intends to file a preliminary proxy statement and an accompanying GOLD universal proxy card with the Securities and Exchange Commission ("SEC") to be used to solicit votes for, among other matters, the election of its slate of highly-qualified director nominees at the 2025 annual meeting of stockholders of Quanterix Corporation, a Delaware corporation (the "Company").

    KENT LAKE STRONGLY ADVISES ALL SHAREHOLDERS OF THE COMPANY TO READ THE PROXY STATEMENT AND OTHER PROXY MATERIALS, INCLUDING ITS GOLD PROXY CARD, AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. SUCH PROXY MATERIALS WILL BE AVAILABLE AT NO CHARGE ON THE SEC'S WEB SITE AT HTTP://WWW.SEC.GOV. IN ADDITION, THE PARTICIPANTS IN THIS PROXY SOLICITATION WILL PROVIDE COPIES OF THE PROXY STATEMENT WITHOUT CHARGE, WHEN AVAILABLE, UPON REQUEST. REQUESTS FOR COPIES SHOULD BE DIRECTED TO THE PARTICIPANTS' PROXY SOLICITOR.

    The participants in the proxy solicitation are currently anticipated to be Kent Lake Partners, Kent Lake PR LLC ("Kent Lake PR") and Benjamin Natter (collectively, the "Kent Lake Parties"); and Alexander G. Dickinson, Bruce Felt and Hakan Sakul (the "Kent Lake Nominees" and collectively with the Kent Lake Parties, the "Participants").

    As of the date hereof, Kent Lake Partners directly beneficially owned 2,645,086 shares of the Company's Common Stock, $0.001 par value per share (the "Common Stock"). Kent Lake PR, as the investment adviser and as the general partner to Kent Lake Partners, may be deemed to beneficially own the 2,645,086 shares of Common Stock beneficially owned by Kent Lake Partners. Mr. Natter, as the Managing Member of Kent Lake PR, may be deemed to beneficially own the 2,645,086 shares of Common Stock beneficially owned by Kent Lake Partners. None of the Kent Lake Nominees beneficially own any shares of Common Stock. All of the foregoing information is as of the date hereof unless otherwise disclosed.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20250302423208/en/

    Investor Contacts

    Ben Natter, 415-237-0007

    [email protected]

    Saratoga Proxy Consulting LLC

    John Ferguson / Ann Marie Mellone

    (212) 257-1311 / (888) 368-0379

    [email protected]

    Media Contact

    Longacre Square Partners

    [email protected]

    Get the next $AKYA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AKYA
    $CMBM
    $CSCO
    $DOMO

    CompanyDatePrice TargetRatingAnalyst
    ICON plc
    $ICLR
    9/9/2025$175.00Buy → Hold
    Jefferies
    ICON plc
    $ICLR
    9/3/2025$236.00Neutral → Buy
    Rothschild & Co Redburn
    Domo Inc.
    $DOMO
    8/26/2025$21.00Hold → Buy
    TD Cowen
    ICON plc
    $ICLR
    8/21/2025$200.00Buy → Neutral
    Citigroup
    Cisco Systems Inc.
    $CSCO
    8/15/2025$69.00Buy → Hold
    HSBC Securities
    Illumina Inc.
    $ILMN
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    Quanterix Corporation
    $QTRX
    8/11/2025$5.00Buy → Hold
    Canaccord Genuity
    Cisco Systems Inc.
    $CSCO
    7/28/2025$72.00Outperform → In-line
    Evercore ISI
    More analyst ratings

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    ICON plc downgraded by Jefferies with a new price target

    Jefferies downgraded ICON plc from Buy to Hold and set a new price target of $175.00

    9/9/25 7:54:46 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded ICON plc from Neutral to Buy and set a new price target of $236.00

    9/3/25 8:15:57 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Domo upgraded by TD Cowen with a new price target

    TD Cowen upgraded Domo from Hold to Buy and set a new price target of $21.00

    8/26/25 8:09:00 AM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    President & CEO Toloue Masoud covered exercise/tax liability with 254 shares, decreasing direct ownership by 0.05% to 512,938 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    10/2/25 7:31:26 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Director Taraporevala Cyrus

    4 - PFIZER INC (0000078003) (Issuer)

    10/2/25 4:56:13 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Smith James C

    4 - PFIZER INC (0000078003) (Issuer)

    10/2/25 4:56:12 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina launches new business to accelerate technology and data-driven discovery

    New business focuses on developing data assets, software, and AI to fuel life science breakthroughs Expands pharma access to large omics datasets to advance target discovery and drug development SAN DIEGO, Oct. 1, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the launch of BioInsight, a new business within Illumina, developed to meet industry demand for deeper biologic insights driven by the need of researchers and pharma companies to access and interpret ever larger-scale multiomic data. By bringing together Illumina's strengths across sequencing, data analysis, software and AI, BioInsight will empower customers and partners with solutions to identify drug targets, under

    10/1/25 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Domo Recognized in Snowflake's Fourth Annual Modern Marketing Data Stack Report as "One to Watch"

    Domo enables joint customers to build AI-driven solutions that make data visible and actionable on Snowflake's AI Data Cloud SILICON SLOPES, Utah, Sept. 30, 2025 /PRNewswire/ -- Domo (NASDAQ:DOMO) today announced that it has been recognized as a Business Intelligence (BI) One to Watch in Snowflake's annual report, The Modern Marketing Data Stack 2026: How Marketers Become Agents of Change in an AI-Driven World. The fourth annual edition of Snowflake's Modern Marketing Data Stack identifies the technologies, solutions, and platforms adopted by Snowflake customers. The anal

    9/30/25 4:01:00 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    SEC Filings

    View All

    Quanterix Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Quanterix Corp (0001503274) (Filer)

    10/2/25 4:26:42 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 144 filed by ICON plc

    144 - ICON PLC (0001060955) (Subject)

    10/2/25 4:03:11 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 6-K filed by ICON plc

    6-K - ICON PLC (0001060955) (Filer)

    9/24/25 9:06:31 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Sriram Vandana bought $19,878 worth of shares (4,150 units at $4.79), increasing direct ownership by 5% to 87,200 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    9/17/25 10:24:11 AM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Founder and CEO James Joshua G bought $165,897 worth of Class B Common Stock (13,025 units at $12.74), increasing direct ownership by 1% to 1,079,972 units (SEC Form 4)

    4 - DOMO, INC. (0001505952) (Issuer)

    6/23/25 9:37:55 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    Director Walt David R bought $984,968 worth of shares (160,000 units at $6.16), increasing direct ownership by 9% to 1,866,933 units (SEC Form 4)

    4 - Quanterix Corp (0001503274) (Issuer)

    6/13/25 4:39:15 PM ET
    $QTRX
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    Financials

    Live finance-specific insights

    View All

    ICON plc Schedules Third Quarter 2025 Earnings Conference Call

    ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 23, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation. From molecule

    9/24/25 9:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Evolent Announces Strategic Divestiture of its Value-Based Primary Care Business, Evolent Care Partners

    Transaction enhances focus on specialty condition management and accelerates Evolent's deleveraging path.Proceeds from the transaction to be used to prepay senior term debt; Immediately accretive to Evolent's free cash flow by more than $7 million per year.Evolent reiterates outlook for Q3 2025 and full year 2025 for Revenue and Adjusted EBITDA, excluding the effect of the transaction.WASHINGTON, Sept. 23, 2025 /PRNewswire/ -- Evolent Health, Inc. (NYSE:EVH) ("Evolent"), a company focused on achieving better health outcomes for people with complex conditions, today announced that it has agreed to sell its value-based primary care business, Evolent Care Partners ("ECP"), to Privia Health Grou

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care

    Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts

    Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EST on Tuesday, November 4, 2025. The purpose of the call is to provide an update on Pfizer's results, as reflected in the company's Third Quarter 2025 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report, visit our web site at www.pfizer.com/investors. Information on accessing and registering for the webcast will be available at www.pfizer.com/investors beginning today. Participants are advised to register in advance of the conference call. You can also listen to the confer

    9/23/25 10:00:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Domo Inc.

    SC 13G/A - DOMO, INC. (0001505952) (Subject)

    11/14/24 12:25:56 PM ET
    $DOMO
    Computer Software: Prepackaged Software
    Technology

    $AKYA
    $CMBM
    $CSCO
    $DOMO
    Leadership Updates

    Live Leadership Updates

    View All

    Predicta Biosciences Secures $23.4M to Scale its Novel Diagnostic and Analytics Platform for Blood Cancers and Autoimmune Diseases

    Brian McKernan joins as CEO to further advance Predicta's clinical impact, including its non-invasive diagnostic for Multiple Myeloma Predicta Biosciences, a precision oncology company developing novel diagnostic and therapeutic discovery solutions, today announced it has raised an oversubscribed $23.4 million Series A led by Engine Ventures. Additional participating investors include Illumina Ventures, Lightchain Capital, Mass General Brigham Ventures, ACS BrightEdge, Binney Street Capital of Dana-Farber Cancer Institute and Myeloma Solutions Fund. The capital will be used to expand Predicta's team and CLIA-approved lab infrastructure, and advance commercialization of the company's first

    10/1/25 9:00:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Privia Health Expands Value-Based Care Footprint with Acquisition of Accountable Care Organization Business from Evolent Health

    ARLINGTON, Va., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (NASDAQ:PRVA) announced that it signed a definitive agreement to acquire an Accountable Care Organization (ACO) business from Evolent Health, Inc. (NYSE:EVH). The ACO business cares for over 120,000 attributed lives through the Medicare Shared Savings Program (MSSP), as well as various commercial and Medicare Advantage programs. With this transaction, Privia Health will now serve approximately 1.5 million attributed lives in value-based care (VBC) arrangements across commercial, Medicare, Medicare Advantage and Medicaid. Privia Health will pay $100 million in cash at closing and up to an additional $13 million su

    9/23/25 4:10:00 PM ET
    $EVH
    $PRVA
    Other Consumer Services
    Consumer Discretionary
    Medical/Nursing Services
    Health Care